<DOC>
	<DOC>NCT02194075</DOC>
	<brief_summary>Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.</brief_summary>
	<brief_title>Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Fluvoxamine</mesh_term>
	<criteria>Informed consent Met DSMV criteria YBOCS ≥ 16 Course of illness ≥ 1year Age range between 18~40 years old Junior high school education level above Any other psychiatric axisI or axisII disorders History of epileptic seizures or any other neurological disorder Any other clinically relevant abnormalities in their medical history or laboratory examinations; alcohol or drug abuser</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>